Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

ALZHEIMER DISEASE

Follow-up of active Aβ immunization in Alzheimer disease

A new report presents post-mortem neuropathological follow-up of patients 4 months to 15 years after they received active amyloid-β (Aβ) immunization during its first trial in Alzheimer disease. The study documents effects on plaque clearance, tau pathology, plasma anti-Aβ antibody titres and final cognitive status; variability was seen between patients.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Alzhemer’s Association. 2019 Alzheimer’s disease facts and figures. Alzheimers Dement. 15, 321–387 (2019).

    Article  Google Scholar 

  2. Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 8, 595–608 (2016).

    Article  CAS  Google Scholar 

  3. Drummond, E. & Wisniewski, T. Alzheimer’s disease: experimental models and reality. Acta Neuropathol. 133, 155–175 (2017).

    Article  CAS  Google Scholar 

  4. Herline, K., Drummond, E. & Wisniewski, T. Recent advancements toward therapeutic vaccines against Alzheimer’s disease. Expert Rev. Vaccines 17, 707–721 (2018).

    Article  CAS  Google Scholar 

  5. Wisniewski, T. & Goni, F. Immunotherapeutic approaches for Alzheimer’s disease. Neuron 85, 1162–1176 (2015).

    Article  CAS  Google Scholar 

  6. Nicoll, J. A. R. et al. Persistent neuropathological effects 14 years following amyloid-beta immunization in Alzheimer’s disease. Brain https://doi.org/10.1093/brain/awz142 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Bayer, A. J. et al. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology 64, 94–101 (2005).

    Article  CAS  Google Scholar 

  8. Charidimou, A. et al. Emerging concepts in sporadic cerebral amyloid angiopathy. Brain 140, 1829–1850 (2017).

    Article  Google Scholar 

  9. Maarouf, C. L. et al. The biochemical aftermath of anti-amyloid immunotherapy. Mol. Neurodegener. 5, 39 (2010).

    Article  Google Scholar 

  10. Goni, F. et al. Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer’s disease model. Alzheimers Res. Ther. 10, 10 (2018).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Thomas Wisniewski.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wisniewski, T. Follow-up of active Aβ immunization in Alzheimer disease. Nat Rev Neurol 15, 495–496 (2019). https://doi.org/10.1038/s41582-019-0239-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-019-0239-4

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing